Palumbo Wealth Management LLC Purchases New Stake in Dynavax Technologies Co. (NASDAQ:DVAX)

Palumbo Wealth Management LLC purchased a new stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 21,533 shares of the biopharmaceutical company’s stock, valued at approximately $275,000.

Several other hedge funds also recently bought and sold shares of DVAX. Assenagon Asset Management S.A. acquired a new position in Dynavax Technologies in the 3rd quarter worth about $8,291,000. PDT Partners LLC acquired a new position in Dynavax Technologies in the 3rd quarter worth about $3,967,000. Nordea Investment Management AB increased its position in Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock worth $10,034,000 after purchasing an additional 232,690 shares during the last quarter. Mizuho Markets Americas LLC increased its position in Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after purchasing an additional 204,475 shares during the last quarter. Finally, Barclays PLC increased its position in Dynavax Technologies by 137.4% in the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock worth $3,371,000 after purchasing an additional 175,118 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on DVAX shares. HC Wainwright upped their target price on Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. Finally, StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday.

Dynavax Technologies Stock Performance

DVAX opened at $12.82 on Friday. The company has a market cap of $1.69 billion, a PE ratio of 98.62 and a beta of 1.32. The stock has a 50-day moving average of $12.80 and a 200-day moving average of $11.94. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $13.89. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.